Literature DB >> 7664275

Genetic suppressor elements: new tools for molecular oncology--thirteenth Cornelius P. Rhoads Memorial Award Lecture.

I B Roninson1, A V Gudkov, T A Holzmayer, D J Kirschling, A R Kazarov, C R Zelnick, I A Mazo, S Axenovich, R Thimmapaya.   

Abstract

Genetic suppressor elements (GSEs) are short biologically active gene fragments that encode dominantly acting peptides or inhibitory antisense RNAs. GSEs can be isolated from a single gene or from a multigene complex by constructing a library of short random fragments of the target gene(s) in an expression vector, followed by expression selection for the desired phenotype in a suitable cellular system. GSE selection from a single gene allows one to develop efficient and specific inhibitors of the gene function and to identify functional protein domains. GSE selection from a multigene complex, such as a normalized (uniform abundance) cDNA population from mammalian cells, makes it possible to identify genes that are involved in selectable cellular phenotypes. The potential of GSE selection for uncovering novel gene functions was first demonstrated using bacteriophage lambda as a model system. GSE selection in retroviral expression vectors has been applied in mammalian cells to identify genes responsible for sensitivity to etoposide and other chemotherapeutic drugs. GSE selection is also useful for cloning and analysis of tumor suppressor genes and can be applied to identifying tumor-specific targets for future anticancer drugs. Investigators should find this experimental strategy applicable to many different areas of medical and biological research.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7664275

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  A functional genetic screen identifies regions at the C-terminal tail and death-domain of death-associated protein kinase that are critical for its proapoptotic activity.

Authors:  T Raveh; H Berissi; M Eisenstein; T Spivak; A Kimchi
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

2.  Selection of functional tRNA primers and primer binding site sequences from a retroviral combinatorial library: identification of new functional tRNA primers in murine leukemia virus replication.

Authors:  A H Lund; M Duch; F S Pedersen
Journal:  Nucleic Acids Res       Date:  2000-02-01       Impact factor: 16.971

3.  Loss-of-function genetics in mammalian cells: the p53 tumor suppressor model.

Authors:  A Carnero; J D Hudson; G J Hannon; D H Beach
Journal:  Nucleic Acids Res       Date:  2000-06-01       Impact factor: 16.971

4.  Preferential MyoD homodimer formation demonstrated by a general method of dominant negative mutation employing fusion with a lysosomal protease.

Authors:  F Q Li; A Coonrod; M Horwitz
Journal:  J Cell Biol       Date:  1996-11       Impact factor: 10.539

5.  Identification of genetic changes associated with drug resistance by reverse in situ hybridization.

Authors:  S F Hoare; C A Freeman; J C Coutts; J M Varley; L James; W N Keith
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

6.  Functional genetic screening reveals the role of mitochondrial cytochrome b as a mediator of FAS-induced apoptosis.

Authors:  Andrei P Komarov; Oskar W Rokhlin; Chang-An Yu; Andrei V Gudkov
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-16       Impact factor: 11.205

7.  Peptides genetically selected for NF-κB activation cooperate with oncogene Ras and model carcinogenic role of inflammation.

Authors:  Venkatesh Natarajan; Andrei P Komarov; Thomas Ippolito; Kyle Bonneau; Alex A Chenchik; Andrei V Gudkov
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-13       Impact factor: 11.205

8.  A screen for genetic suppressor elements of hepatitis C virus identifies a supercharged protein inhibitor of viral replication.

Authors:  Rudo L Simeon; Zhilei Chen
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

9.  Identification of novel cancer therapeutic targets using a designed and pooled shRNA library screen.

Authors:  David Oliver; Hao Ji; Piaomu Liu; Alexander Gasparian; Ellen Gardiner; Samuel Lee; Adrian Zenteno; Lillian O Perinskaya; Mengqian Chen; Phillip Buckhaults; Eugenia Broude; Michael D Wyatt; Homayoun Valafar; Edsel Peña; Michael Shtutman
Journal:  Sci Rep       Date:  2017-02-22       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.